Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E19.15 EPS (ttm)3.54 Insider Own0.10% Shs Outstand1.48B Perf Week-2.07%
Market Cap100.24B Forward P/E7.17 EPS next Y9.44 Insider Trans0.55% Shs Float1.48B Perf Month-14.03%
Income5.42B PEG3.64 EPS next Q2.20 Inst Own70.90% Short Float1.91% Perf Quarter-13.90%
Sales32.65B P/S3.07 EPS this Y4.80% Inst Trans0.32% Short Ratio3.07 Perf Half Y-23.61%
Book/sh-5.29 P/B- EPS next Y7.38% ROA8.70% Target Price84.92 Perf Year-23.82%
Cash/sh3.53 P/C19.17 EPS next 5Y5.27% ROE-94.50% 52W Range65.06 - 100.23 Perf YTD-26.53%
Dividend4.28 P/FCF14.04 EPS past 5Y7.60% ROI21.80% 52W High-32.43% Beta0.93
Dividend %6.32% Quick Ratio0.90 Sales past 5Y11.80% Gross Margin77.30% 52W Low4.11% ATR1.81
Employees30000 Current Ratio1.00 Sales Q/Q-1.30% Oper. Margin19.90% RSI (14)31.22 Volatility1.46% 2.52%
OptionableYes Debt/Eq- EPS Q/Q-5.10% Profit Margin16.30% Rel Volume0.87 Prev Close68.00
ShortableYes LT Debt/Eq- EarningsJul 26 BMO Payout113.20% Avg Volume9.19M Price67.73
Recom2.50 SMA20-4.51% SMA50-10.17% SMA200-17.18% Volume7,956,479 Change-0.40%
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Oct-22-18Reiterated SunTrust Buy $157 → $135
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Jul-23-19 05:41PM  Merck's biosimilar to AbbVie's Humira wins FDA approval Reuters
05:36PM  CEO calls it an 'important day for women's health.' Wall Street appears unimpressed American City Business Journals
04:00PM  How to Invest in Cancer-Fighting Stocks Motley Fool
03:17PM  Celgene, Bristol-Myers and AbbVie still to report earnings this week: Heres what to expect MarketWatch
02:03PM  Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings InvestorPlace
11:58AM  AbbVie (ABBV) Set to Report Q2 Earnings: What to Expect Zacks
10:34AM  Top Ranked Value Stocks to Buy for July 23rd Zacks
10:18AM  The AbbVie-Allergan Merger Is the Most Positive of the Pharma Deals Barrons.com
10:16AM  Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View Zacks
08:13AM  Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings? Zacks
Jul-22-19 05:45PM  AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know Zacks
10:55AM  Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy Zacks
10:06AM  Can Allergan (AGN) Keep the Earnings Streak Alive in Q2? Zacks
09:55AM  Is a Beat in Store for AbbVie (ABBV) This Earnings Season? Zacks
12:06AM  The Parnassus Fund Exits Mattel, Sells Alphabet GuruFocus.com
Jul-21-19 12:10PM  AbbVie's Acquisitions Report Card Shows Investors Have a Reason to Worry About the Allergan Buyout Motley Fool
09:00AM  Better Buy: Pfizer vs. AbbVie Motley Fool
Jul-20-19 12:07PM  8 More Big Pharma Events in 2019 You Don't Want to Miss Motley Fool
Jul-19-19 04:58PM  The 3 Top Stocks for Dividends Every Calendar Month GuruFocus.com
10:30AM  AbbVie (ABBV) Earnings Expected to Grow: Should You Buy? Zacks
09:53AM  Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus Zacks
Jul-18-19 05:23PM  3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement Zacks
10:34AM  Novartis's Pure Play in Pharma Works, for Now Bloomberg
10:26AM  AC Immune Initiates Phase I Study for Alzheimer's Disease Zacks
09:58AM  Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance Zacks
08:21AM  3 Top Dividend Stocks With Yields Over 4% Motley Fool
Jul-17-19 10:53AM  Health care 'Cadillac Tax' repeal bill up for vote Wednesday Yahoo Finance Video
09:10AM  Should Value Investors Buy AbbVie (ABBV) Stock? Zacks
09:00AM  AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know Zacks
08:45AM  AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why Zacks
Jul-16-19 04:09PM  AbbVie Buys Allergan for $63 Billion Meredith Videos
11:04AM  AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio Zacks
10:23AM  J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View Zacks
09:49AM  Allergan Stock Wont Rise Much More, Analyst Says, in Looking at Deal With AbbVie Barrons.com
Jul-15-19 05:45PM  AbbVie (ABBV) Gains But Lags Market: What You Should Know Zacks
08:53AM  AbbVie Acquires Mavupharma For Undisclosed Amount Benzinga
08:00AM  AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma PR Newswire
Jul-14-19 11:10AM  Health companies start reporting earnings next week: Here are 3 things to keep in mind MarketWatch
09:00AM  Is Allergan a Buy? Motley Fool
Jul-13-19 07:00AM  Better Buy: AbbVie vs. Merck Motley Fool
Jul-11-19 11:14AM  FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Zacks
08:00AM  AbbVie to Host Second-Quarter 2019 Earnings Conference Call PR Newswire
07:53AM  J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store? Zacks
07:24AM  2 Falling Pharma Stocks Whose Star May Rise in 2019 TipRanks
Jul-10-19 11:57AM  Analyst: CytomX Therapeutics Validated By AbbVie Decision Benzinga
08:41AM  Megadeals Enter Biotech Realm And 3 Other Trends To Watch In 2019 Investor's Business Daily
08:14AM  Will Patent Woes Boost Pharma Stock Megamergers Further? Zacks
06:00AM  AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue PR Newswire
Jul-09-19 05:45PM  AbbVie (ABBV) Gains But Lags Market: What You Should Know Zacks
01:52PM  The S&P 500s 5 Best Highest-Yielding Dividend Stocks InvestorPlace
08:00AM  AbbVie Stock Is Poised To Become A Top 5 Pharma But Should You Buy It? Investor's Business Daily
Jul-08-19 06:03PM  3 Dividend Stocks Retirees Must Have in Their Portfolios GuruFocus.com
06:02PM  ObsEva Ends Recruitment in Second Uterine Fibroids Study Zacks
10:34AM  The Zacks Analyst Blog Highlights: Amazon, UnitedHealth, AbbVie, Simon Property and Autodesk Zacks
09:41AM  AbbVie (ABBV) Shares Down So Far This Year: Here's Why Zacks
09:15AM  Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice Zacks
Jul-05-19 08:53PM  The Stock Market May Be Pointing to Trumps Reelection Barrons.com
02:47PM  Top Stock Reports for Amazon, UnitedHealth & AbbVie Zacks
11:42AM  AbbVie Falls 3% Investing.com
Jul-04-19 12:35PM  Why AbbVie's Stock Sank in the First Half of 2019 Motley Fool
07:04AM  3 Dividend Stocks That Pay You More Than Exxon Does Motley Fool
Jul-03-19 04:38PM  Two Dividend Payers That Beat the SP 500 Kiplinger
10:41AM  Biotech Braces for Busy Summer as 2019 M&A Volume Heats Up Bloomberg
09:34AM  Will the Pharma Space Witness More Mega-Merger Deals in 2H? Zacks
Jul-02-19 05:08PM  Is AbbVie a Buy? Motley Fool
04:34PM  Why This Gilead-AbbVie Rivalry Could Come To A Head In 2020 Investor's Business Daily
01:45PM  IBM Is Set to Join Exclusive Group of Dividend Aristocrats Bloomberg
10:43AM  AbbVies Allergan Acquisition Sowed Doubts on Wall Street. Some Analysts Are Coming Around. Barrons.com
10:15AM  3 Biotechs That Have Doubled This Year (Acquisition Next?) Motley Fool
09:54AM  Gilead to Submit NDA for Inflammation Drug Filgotinib in '19 Zacks
09:12AM  Gilead Surges in the Race for Next Big Anti-Inflammatory Drug Barrons.com
Jul-01-19 11:00PM  Patent panic gives green light to mega pharma deals Financial Times
05:45PM  AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know Zacks
09:43AM  Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval Zacks
06:38AM  Acquisition Improves the Outlook of Pfizer Stock InvestorPlace
Jun-30-19 10:09AM  Notable Insider Buys This Past Week: AbbVie, MGM and More Benzinga
10:00AM  Barron's Picks And Pans: AbbVie, Crocs, RealReal, Roku And More Benzinga
09:01AM  The 10 Highest-Yielding Dividend Stocks in the S&P 500 Motley Fool
08:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
07:00AM  4 Reasons to Buy AbbVie Now That It's Acquiring Allergan Motley Fool
Jun-29-19 05:21PM  How PayPal Holdings Inc and Other Hedge Fund Favorites Performed in Q2 Insider Monkey
Jun-28-19 08:00PM  For Apple, China Is an Irritant, and Wind of Opportunity Barrons.com
08:00PM  AbbVie Is Buying Allergan. Thats Not the Right Remedy for the Stock. Barrons.com
06:25PM  After AbbVie Stock Crashed, Three Insiders Loaded Up on Shares Barrons.com
04:12PM  Stock Market Rally Awaits Trump-Xi Outcome; Micron Lifts Chips, Boeing 737 Max Flaw Found Investor's Business Daily
12:30PM  6 Dividend Stocks That Beat the S&P 500 Barrons.com
12:05PM  4 Lower-Risk Healthcare Picks for Long-Term Investors Motley Fool
10:17AM  Are AbbVie and Allergan Really Better Together? Motley Fool
09:44AM  Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger Zacks
09:15AM  AbbVie Rises 3% Investing.com
07:00AM  Almost $500 Billion of Megadeals Get Panned Instantly Bloomberg
Jun-27-19 12:31PM  CORRECTED-US loan market ready to feast on AbbVie's jumbo US$38bn bridge loan Reuters
09:47AM  Big Pharma Gets Bigger Motley Fool
07:07AM  AbbVie Rises 3% Investing.com
05:20AM  Price of these promising drug-related stocks shows investors are too cautious about the healthcare sector MarketWatch
Jun-26-19 05:51PM  Is Allergan a Good Deal for AbbVie? Zacks
04:40PM  AbbVie Rebounds as Market Warms to Allergan Deal, Botox Potential TheStreet.com
04:17PM  AbbVie Is 'The New Cash King' As It Takes On Botox-Maker Allergan Investor's Business Daily
02:31PM  Morphic Holding IPO: What You Need To Know Benzinga
12:26PM  Elliott Management Advocated for an Allergan Split Prior to Sale Bloomberg
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AUSTIN ROXANNE SDirectorJun 26Buy67.5011,500776,25052,114Jun 28 04:47 PM
CHASE WILLIAM JEVP, Finance & AdministrationJun 26Buy67.3030,4002,045,920169,552Jun 28 04:47 PM
RAPP EDWARD JDirectorJun 26Buy67.307,500504,75030,662Jun 28 04:48 PM
Durkin Brian LVP, ControllerMar 25Sale79.6947537,8539,121Mar 25 04:34 PM
Schumacher Laura JVice ChairmanMar 14Sale80.0025,0002,000,000139,838Mar 15 05:53 PM
SALEKI-GERHARDT AZITAEVP, OperationsMar 05Sale79.0315,7971,248,48093,312Mar 06 05:03 PM
Schumacher Laura JVice ChairmanDec 28Sale90.0025,0002,250,000134,322Jan 02 04:49 PM
CHASE WILLIAM JEVP, Finance & AdministrationDec 12Sale90.0060,0005,400,000104,863Dec 14 05:12 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 11Sale88.7516,8501,495,438286,203Dec 13 04:56 PM
Schumacher Laura JExecutive Vice PresidentDec 04Option Exercise51.4294,1404,840,679192,398Dec 07 05:15 PM
Schumacher Laura JExecutive Vice PresidentDec 04Sale93.5894,1408,809,55298,258Dec 07 05:15 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 29Sale90.1042,4503,824,94030,350Nov 30 05:22 PM
SEVERINO MICHAELEVP, R&D and CSOAug 17Sale97.5250,0004,876,06082,281Aug 21 04:58 PM